Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Onyvax P: Phase II data

In an open-label U.K. Phase II trial in 48 patients, median progression-free survival in the first cohort

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE